Canaccord Genuity analyst John Newman was out pounding the table on Agios Pharmaceuticals (NASDAQ:AGIO) Tuesday, reiterating a Buy rating and a price target of …
In a research report sent to investors today, Canaccord Genuity analyst John Newman maintained a Buy rating on Agios Pharma (NASDAQ:AGIO) and raised his …
In a research report released Monday, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral rating and a price …